1. Home
  2. INSW vs XENE Comparison

INSW vs XENE Comparison

Compare INSW & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INSW

International Seaways Inc.

N/A

Current Price

$73.12

Market Cap

2.8B

Sector

Technology

ML Signal

N/A

XENE

Xenon Pharmaceuticals Inc.

N/A

Current Price

$60.45

Market Cap

3.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INSW
XENE
Founded
1999
1996
Country
United States
Canada
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.2B
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
INSW
XENE
Price
$73.12
$60.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
10
Target Price
$64.00
$53.70
AVG Volume (30 Days)
565.0K
854.0K
Earning Date
05-29-2026
05-28-2026
Dividend Yield
6.05%
N/A
EPS Growth
N/A
N/A
EPS
6.23
N/A
Revenue
$843,302,000.00
$311,000.00
Revenue This Year
$2.80
N/A
Revenue Next Year
N/A
$1,645.94
P/E Ratio
$11.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.20
$26.74
52 Week High
$78.51
$46.99

Technical Indicators

Market Signals
Indicator
INSW
XENE
Relative Strength Index (RSI) 61.06 77.84
Support Level $46.84 $37.91
Resistance Level $78.51 N/A
Average True Range (ATR) 2.76 2.08
MACD -0.01 1.72
Stochastic Oscillator 58.83 88.73

Price Performance

Historical Comparison
INSW
XENE

About INSW International Seaways Inc.

International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.

About XENE Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Share on Social Networks: